TD Cowen raised the firm’s price target on Ceribell (CBLL) to $29 from $20 and keeps a Buy rating on the shares after the company announced that it has received FDA 510(k) clearance for its delirium monitoring solution. The clearance, making its system the first and only U.S.-approved device for delirium screening and monitoring, comes months ahead of expectations and will significantly expand the company’s total addressable market for adult seizure detection, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell, Inc. Gains FDA Clearance for Delirium Device
- Ceribell receives FDA 510k clearance for delirium screening, monitoring device
- Ceribell management to meet virtually with BTIG
- Ceribell Gains FDA Clearance for Seizure Detection Algorithm
- Ceribell’s Strategic Expansion and Growth Potential with FDA Clearance for Clarity Algorithm